Long-term outcomes of the randomized controlled trial comparing 5-aminolaevulinic acid and Photofrin photodynamic therapy for Barrett’s oesophagus related neoplasia

References

• Cancer Research UK [Internet]. Cancer Statistics; [cited 2015 Dec 22]. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats
   Google Scholar
• Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143:336–346.
   PubMed Web of Science ®Google Scholar
• Peyre CG, Watson TJ. Surgical management of Barrett's esophagus. Gastroenterol Clin N Am. 2015;44:459–471.
   PubMed Web of Science ®Google Scholar
• Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc. 2007;66:460–468.
   PubMed Web of Science ®Google Scholar
• Haidry RJ, Dunn JM, Butt MA, et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology. 2013;145:87–95.
   PubMed Web of Science ®Google Scholar
• Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63:7–42.
   PubMed Web of Science ®Google Scholar
• Haidry R, Lovat L, Sharma P. Radiofrequency ablation for Barrett's dysplasia: past, present and the future? Curr Gastroenterol Rep. 2015;17:13.
   PubMedGoogle Scholar
• Dunn JM, Mackenzie GD, Banks MR, et al. A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett's oesophagus. Lasers Med Sci. 2013;28:707–715.
   PubMed Web of Science ®Google Scholar
• Mackenzie GD, Jamieson NF, Novelli MR, et al. How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett's esophagus. Lasers Med Sci. 2008;23:203–210.
   PubMed Web of Science ®Google Scholar
• Mackenzie GD, Dunn JM, Selvasekar CR, et al. Optimal conditions for successful ablation of high-grade dysplasia in Barrett's oesophagus using aminolaevulinic acid photodynamic therapy. Lasers Med Sci. 2009;24:729–734.
   PubMed Web of Science ®Google Scholar
• Lovat LB, Jamieson NF, Novelli MR, et al. Photodynamic therapy with m-tetrahydroxyphenyl chlorin for high-grade dysplasia and early cancer in Barrett's columnar lined esophagus. Gastrointest Endosc. 2005;62:617–623.
   PubMed Web of Science ®Google Scholar
• Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.
   PubMed Web of Science ®Google Scholar
• Haidry RJ, Butt MA, Dunn JM, et al. Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry. Gut. 2015;64:1192–1199.
   PubMed Web of Science ®Google Scholar
• Haidry R, Lovat L. Long-term durability of radiofrequency ablation for Barrett's-related neoplasia. Curr Opin Gastroenterol. 2015;31:316–320.
   PubMed Web of Science ®Google Scholar
• Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal neoplasia. Gut. 2000;47:251–255.
   PubMed Web of Science ®Google Scholar
• Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut. 2002;51:130–131.
   PubMed Web of Science ®Google Scholar
• Haidry RJ, Lipman G, Banks MR, et al. Comparing outcome of radiofrequency ablation in Barrett’s with high grade dysplasia and intramucosal carcinoma: a prospective multicenter UK registry. Endoscopy. 2015;47:980–987.
   PubMed Web of Science ®Google Scholar
• Dunn JM, Banks MR, Oukrif D, et al. Radiofrequency ablation is effective for the treatment of high-grade dysplasia in Barrett's esophagus after failed photodynamic therapy. Endoscopy. 2011;43:627–630.
   PubMed Web of Science ®Google Scholar
• Prasad GA, Wang KK, Halling KC, et al. Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. Cancer. 2008;113:470–476.
   PubMed Web of Science ®Google Scholar
• Prasad GA, Wang KK, Halling KC, et al. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology. 2008;135:370–379.
   PubMed Web of Science ®Google Scholar
• Timmer MR, Brankley SM, Gorospe EC, et al. Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers. Gastrointest Endosc. 2014;80:984–991.
   PubMed Web of Science ®Google Scholar
• Dunn JM, Mackenzie GD, Oukrif D, et al. Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy. Br J Cancer. 2010;102:1608–1617.
   PubMed Web of Science ®Google Scholar
• Zeki SS, Haidry R, Graham TA, et al. Clonal selection and persistence in dysplastic Barrett's esophagus and intramucosal cancers after failed radiofrequency ablation. Am J Gastroenterol. 2013;108:1584–1592.
   PubMed Web of Science ®Google Scholar
• Martinez P, Timmer MR, Lau CT, et al. Dynamic clonal equilibrium and predetermined cancer risk in Barrett’s oesophagus. Nat Commun. 2016;7:12158.
   PubMed Web of Science ®Google Scholar
• Maley CC, Galipeau PC, Li X, et al. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett’s esophagus. Cancer Res. 2004;64:3414–3427.
   PubMed Web of Science ®Google Scholar
• Kohoutova D, Haidry R, Banks M, et al. Esophageal neoplasia arising from subsquamous buried glands after an apparently successful photodynamic therapy or radiofrequency ablation for Barrett's associated neoplasia. Scand J Gastroenterol. 2015;50:1315–1321.
   PubMed Web of Science ®Google Scholar